CA-ZYNGA
5.5.2021 22:07:12 CEST | Business Wire | Press release
Zynga Inc. (Nasdaq: ZNGA) today released financial results for its first quarter ended March 31, 2021 by posting management’s Q1 2021 Quarterly Earnings Letter to its Investor Relations website. Please see the attached Quarterly Earnings Letter or visit http://investor.zynga.com/financial-information/quarterly-results to access the letter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005238/en/
“We are off to an excellent start in 2021 with record Q1 results driven by breakout performances from our live services, new games and hyper-casual portfolio,” said Frank Gibeau, Chief Executive Officer at Zynga. “Today, we announced our intent to acquire Chartboost, a leading advertising and monetization platform. This transformational acquisition will combine Zynga’s high-quality games portfolio and first-party data with Chartboost’s proven advertising and monetization platform to create a new level of audience scale and meaningfully enhance our competitive advantage in the mobile ecosystem.”
Q1 Growth Highlights:
Record Quarterly Revenue and Bookings Driven by our Live Services Portfolio:
- Delivered best quarterly revenue and bookings performances in Zynga history, driven by an all-time best revenue and bookings quarter for our Social Slots portfolio, in addition to our highest Q1 performances by Empires & Puzzles , Words With Friends , CSR2 and our Casual Cards portfolio. Harry Potter: Puzzles & Spells also continues to build momentum and was a meaningful contributor to our live services growth.
- Record average mobile daily active users (DAUs) of 38 million, up 85% year-over-year, and average mobile monthly active users (MAUs) of 164 million, up 139% year-over-year, primarily driven by our recent additions of Toon Blast , Toy Blast and Rollic’s hyper-casual portfolio.
Recently Launched Puzzle Combat with Additional New Title Launches Planned in 2021 and Beyond:
- In April, we launched Puzzle Combat worldwide, and early player engagement gives us confidence in our ability to gradually scale the game over the coming quarters.
- As we progress through 2021, we expect to release FarmVille 3 worldwide and Star Wars: Hunters™ worldwide.
Success in Hyper-Casual Continues with Rollic’s Games Topping the Charts:
- Rollic, one of the fastest-growing hyper-casual companies in the world, delivered its all-time best revenue and bookings quarter with its launches of High Heels! and Blob Runner 3D , which reached the #1 and #2 top free downloaded games positions in the U.S. App Store, respectively.
- Rollic is attracting new audiences into Zynga’s network by creating universally fun games that are trending in popular culture and leading social media networks including TikTok.
Cross-Platform Play Development Expands with Announcement of Star Wars: Hunters and Acquisition of Echtra:
- We announced our first cross-platform play title will be Star Wars: Hunters , a free-to-play competitive arena combat game made in collaboration with Lucasfilm Games that will be coming to mobile and Nintendo Switch players later in 2021.
- Acquired Echtra Games, a talented development team with extensive cross-platform play tools and experience to develop a new action role-playing game.
Record International Revenue and Bookings with Asia a Key Contributor:
- Achieved record Q1 international revenue and bookings primarily driven by Toon Blast , Empires & Puzzles , Rollic’s hyper-casual portfolio, Toy Blast and Harry Potter: Puzzles & Spells .
- Asia continues to be a key driver of our international growth, and we are seeing positive early results with High Heels! and Blob Runner 3D both reaching the #1 top free downloaded games position in the China App Store.
Transformational Ad Tech Acquisition Accelerates Zynga’s Advertising Platform Strategy:
- Today, we announced that we entered into an agreement to acquire Chartboost, a leading mobile advertising and monetization platform, with a massive global audience base of more than 700 million monthly users and a broad network of advertising and publishing partners.
- The addition of Chartboost’s scale and ad tech capabilities, combined with our high-quality games portfolio and first-party data, will meaningfully enhance Zynga’s competitive advantage within the mobile ecosystem.
- Zynga will acquire Chartboost for approximately $250 million in cash, subject to customary closing adjustments. Following the anticipated close of this transaction in Q3 2021, Chartboost is expected to be immediately accretive to Zynga while unlocking additional growth and margin expansion opportunities in 2022 and beyond.
Zynga management will also host a conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) today to discuss the company’s results. Questions may be asked on the call and Zynga will respond to as many questions as possible.
The conference call can be accessed at http://investor.zynga.com – a replay of which will be available through the website after the call – or via the below conference dial-in number:
- Toll-Free Dial-In Number: (800) 537-0745
- International Dial-In Number: (253) 237-1142
- Conference ID: 7974907
About Zynga Inc.
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing ™, Empires & Puzzles ™, Merge Dragons! ™, Merge Magic! ™, Toon Blast ™, Toy Blast ™, Words With Friends ™ and Zynga Poker ™. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter , Instagram , Facebook or the Zynga blog .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, relating to, among other things, the proposed acquisition of Chartboost, Inc. (“Chartboost”); our ability to achieve the intended benefits of combining with Chartboost, including expanding our global audience and effectively competing in the mobile advertising industry; our expectations regarding the future launch of new games under development; our expectations regarding international expansion and adoption of our games; and our business objectives and opportunities for future growth. Forward-looking statements often include words such as “outlook,” “projected,” “planned,” “intends,” “will,” “anticipate,” “believe,” “target,” “expect,” and statements in the future tense are generally forward-looking. These forward-looking statements are not guarantees of future performance and reflect management’s current expectations. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties and assumptions is or will be described in greater detail in our public filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at http://investor.zynga.com or the SEC’s website at www.sec.gov .
Editor’s Note:
To download Zynga’s B-roll footage and key art for its games, please visit: https://zynga.social/6kt
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005238/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
